Valuation: Assembly Biosciences, Inc.

Market Cap 550M 481M 442M 412M 781M 52.34B 793M 5.3B 2.06B 25.73B 2.06B 2.02B 88.66B P/E 2026 *
-25.6x
P/E 2027 * -9.68x
Enterprise Value 550M 481M 442M 412M 781M 52.34B 793M 5.3B 2.06B 25.73B 2.06B 2.02B 88.66B EV / Sales 2026 *
12.1x
EV / Sales 2027 * 17x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day+3.93%
1 week+3.74%
Current month+0.95%
1 month+15.06%
3 months-4.38%
6 months-17.80%
Current year-18.44%
1 week 25.95
Extreme 25.95
28.37
1 month 21.8
Extreme 21.795
28.37
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 14/12/2017
Director/Board Member 54 20/10/2020
Chairman 70 04/06/2026
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Chief Financial Officer

-29 0.0002%
06-04Free

Chairman

8,000 0.0514%
06-04Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%+3.74%+52.92%+116.04% 550M
+1.70%+7.41%+2.50%+8.22% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+8.30%+40.44% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+14.00%+19.59% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.35%+6.68%+76.49%+120.03% 24.62B
Weighted average by Cap. +2.07%+6.55%+90.11%+137.86%

Financials

2026 *2027 *
Net sales 45.47M 39.75M 36.53M 34.05M 64.58M 4.33B 65.56M 439M 170M 2.13B 171M 167M 7.33B 32.25M 28.19M 25.91M 24.15M 45.81M 3.07B 46.5M 311M 121M 1.51B 121M 118M 5.2B
Net income -20.46M -17.89M -16.44M -15.32M -29.06M -1.95B -29.51M -197M -76.72M -958M -76.81M -75.16M -3.3B -56.38M -49.29M -45.29M -42.22M -80.08M -5.37B -81.29M -544M -211M -2.64B -212M -207M -9.09B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
02/07/26 $27.74 +3.93% 199,257
01/07/26 $26.69 -2.87% 204,110
30/06/26 $27.48 +1.93% 249,382
29/06/26 $26.96 +0.82% 236,137
26/06/26 $26.74 +10.22% 1,589,358
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.74USD
Average target price
50.00USD
Spread / Average Target
+80.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock